{"id":390658,"date":"2018-06-07T00:00:00","date_gmt":"2018-06-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0026-2018-biopharma-alzheimers-disease-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-04-24T11:29:35","modified_gmt":"2026-04-24T11:29:35","slug":"algocg0026-2018-biopharma-alzheimers-disease-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0026-2018-biopharma-alzheimers-disease-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Alzheimer&#8217;s Disease | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p>For the estimated 3.4 million people in the United States who suffer from Alzheimer\u2019s disease (<abbr title=\"Alzheimer's disease\">AD<\/abbr>), approved therapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantine) that deliver modest efficacy of limited duration. Understanding today\u2019s treatment landscape is important for emerging players as the heavily generic <abbr title=\"Alzheimer's disease\">AD<\/abbr> market braces for the potential entry of a variety of new, high-cost brands\u2014namely, landmark disease-modifying therapies and new behavioral adjuncts. Our <em>Treatment Algorithms: Claims Data Analysis <\/em>content provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and\u00a0recently treated patients.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of treatment in newly diagnosed <abbr title=\"Alzheimer's disease\">AD<\/abbr> patients? What are the quarterly trends in prescribing among recentlytreated and newly diagnosed <abbr title=\"Alzheimer's disease\">AD<\/abbr> patients?<\/li>\n<li>How has Namzaric been integrated into the <abbr title=\"Alzheimer's disease\">AD<\/abbr> treatment algorithm?<\/li>\n<li>What proportion of <abbr title=\"Alzheimer's disease\">AD<\/abbr> patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"Alzheimer's disease\">AD<\/abbr> patients are treated with monotherapy versus combination therapy?\u00a0What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with <abbr title=\"Alzheimer's disease\">AD<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em> provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Real-world data: <\/strong>Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key companies: <\/strong>Allergan, Novartis<\/p>\n<p><strong>Key drugs: <\/strong> Donepezil, galantamine, rivastigmine, rivastigmine patch, memantine <abbr title=\"immediate release\">IR<\/abbr>, Namenda <abbr title=\"extended release\">XR<\/abbr>, Namzaric<\/p>\n<p><strong>Key analysis provided:<\/strong><\/p>\n<ul>\n<li>Brand use across longitudinal patient sample.<\/li>\n<li>Newly diagnosed patient analysis.<\/li>\n<li>Treatment initiation and progression.<\/li>\n<li>Line of therapy analysis.<\/li>\n<li>Combination therapy analysis.<\/li>\n<li>Source of business for recently treated patients.<\/li>\n<li>Persistency and compliance analysis.<\/li>\n<li>Product-level patient flowcharts.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390658","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390658\/revisions"}],"predecessor-version":[{"id":393782,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390658\/revisions\/393782"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}